National Institute of Health Dr. Ricardo Jorge
Repositório Científico do Instituto Nacional de SaúdeNot a member yet
9086 research outputs found
Sort by
Avaliação da sensibilidade aos fármacos em tuberculose (método molecular e fenotípico), resultados do PNAEQ (2018-2022)
Get PDFA deteção das resistências permite adotar um esquema terapêutico adequado contribuindo desta forma para o aumento do sucesso terapêutico e para a diminuição da mortalidade e das taxas de recidiva. Os métodos moleculares permitem a rápida deteção das mutações mais frequentes que conferem resistências e por isso a sua utilização é recomendada pela Organização Mundial de Saúde (OMS) e pela Direção Geral da Saúde (DGS). O método fenotípico permite confirmar os resultados dos testes moleculares e testar outros fármacos importantes para definir o esquema terapêutico adequado a cada caso.
A participação em programas de avaliação externa da qualidade permite aos laboratórios que determinam a sensibilidade aos fármacos em tuberculose avaliarem os seus resultados e, se necessário, corrigirem procedimentos. O objetivo deste trabalho é avaliar o desempenho dos participantes do Programa Nacional de Avaliação Externa da Qualidade PNAEQ) nos 2 programas Micobacteriologia, deteção molecular de multirresistência (DMMR) e Micobacteriologia, avaliação da sensibilidade aos fármacos de 1 ª linha (TSA) no período 2018-2022.info:eu-repo/semantics/publishedVersio
Evaluating a training programe: European Health Information Training Programme - EHITP
Get PDFResumo da apresentação publicado em: Gac Sanit. 2023;37(S1):S177–S325. Disponível em: https://www.gacetasanitaria.org/es-pdf-X0213911123036410?local=trueBackground:
The InfAct (Information for Action) is a Joint Action of the European Commission’s 3rd Health Programme with the main goal to build an infrastructure of a health information system for a stronger European Union and to strengthen its core elements.
The InfAct Joint Action was developed along 36 months and structured in 10 work packages.
Portugal co-led the Work Package 6 (WP6) of this project, which included the development of the proposal of a flagship capacity building programme - the European Health Information Training Programme - and its evaluation. The evaluation objectives included: to evaluate the adequacy of the training programme to the health information needs in the European Member States; to identify possible changes regarding the participants selection process, the training activities and the pedagogical project; and to contribute to the understanding of the potential of the programme to add to available offers in learning on the topics of Public Health information, on the capacity building and behavioural changes in Public Health activities which can be attributed to the course, and of the potential of the programme to contribute to the alignment of health information criteria and procedures between the European Member States.
Methods:
The evaluation process was developed using an observational descriptive study design using a mixed methodological approach with both document analysis and primary data collected by questionnaires and interviews analysis. Mixed quantitative and qualitative data collection methods and analysis were used.
Results
The proposal of the European Health Information Training Programme seemed adequate to the formative needs and capacities in line with the work performed by the InfAct project. In what concerns about its main thematic areas, it was also aligned with the areas identified in the previous formative needs and capacities mapping. The participants selection process proposed seemed, in general, adequate. The potential of the European Health Information Training Programme proposal to learning, capacity building and behavioral changes at work attributable to the course was considered positive, as well as the potential to the alignment of health information criteria and procedures between European Union Member States.
Discussion
In general, we found high consistency between the results obtained from data collected by the techniques used. However, different suggestions for improvement were outlined by the evaluation study population.Project '801553 InfAct' which has received funding from the European Union’s Health Programme (2014-2020). InfAct (Information for Action) is a JA on health information (HI). HI is essential to build up country specific and cross-country knowledge. HI is the basis to inform national health policies, to steer population health investment decisions, to assess the effectiveness of different approaches to enhance population health through promotion, prevention, treatments and care. Timely, up-to-date HI is also vital in framing EU wide programs and policies.info:eu-repo/semantics/publishedVersio
Infográfico - Obesidade Infantil 2022
No full textRelatório COSI Portugal 2022: http://repositorio.insa.pt/handle/10400.18/8630O INSA coordena, desde 2008, o sistema
de vigilância nutricional infantil
– COSI Portugal. Este sistema, integrado
na rede europeia da Organização
Mundial da Saúde, efetua a vigilância
e monitorização do estado
nutricional infantil a cada 3 anos. Para uma melhor disseminação de resultados obtidos sobre vários tópicos relacionados com a saúde dos portugueses, o Instituto Nacional de Saúde Doutor Ricardo Jorge, através do seu Departamento de Alimentação e Nutrição, disponibiliza um infográfico sobre a obesidade infantil. O infográfico apresentado tem como fonte de dados o Sistema de Vigilância Nutricional Infantil − COSI Portugal, referente aos dados de prevalência de excesso e obesidade infantil da 6.ª ronda, realizada no ano letivo 2021/2022 numa amostra representativa nacional de escolas públicas do 1.º ciclo do Ensino Básico (EB) português.info:eu-repo/semantics/publishedVersio
Functional studies of APOB variants the experience of the Portuguese Familial Hypercholesterolemia Study
No full textFamilial hypercholesterolemia (FH) is clinically characterized by increased levels of circulating LDL cholesterol leading to premature coronary heart disease. It can be caused by variants in LDLR, APOB, and PCSK9 genes. APOB variants are responsible for 5-10% of the FH cases, p.(Arg3527Gln) being the most common. Only recently the whole gene has been sequenced due to Next Generation Sequencing, increasing the variant spectrum of APOB and with it the number of variants that need to be functionally assessed. We aimed to characterize novel APOB variants identified in patients included in the Portuguese FH Study to confirm if they are the genetic cause of hypercholesterolemia.
To better analyze these variants, we also create a database with all APOB rare variants found up to date in the Portuguese FH Study. The functional study of 5 variants is ongoing. To access if these variants affect apoB:LDL receptor binding, LDL from index cases and relatives with the variants was separated using sequential ultracentrifugation, and proliferation assays were performed with U937 cells. These cells do not synthesize cholesterol and they depend on apoB:LDL receptor binding to grow.info:eu-repo/semantics/publishedVersio
5th International Conference on Food Contaminants (ICFC2023): Challenges on Exposure Assessment, health impact and sustainability of food systems: Book of Abstracts
No full textThe “5th International Conference on Food Contaminants: Challenges on exposure assessment, health impact and sustainability of food systems”(ICFC2023) took place between 4 and 6th september and was held at the Instituto Agronómico de Campinas, Brazil. This event, under the responsibility of INSA, was held in a hybrid format, in a close collaboration with CESAM, University of Aveiro and the Faculty of Animal Science and Food Engineering, University of S. Paulo, with the support of FAPESP and SCBTA.
The event took place for the first time outside Portugal with the motto “Let's Open Horizonts” with the aim of contributing to strengthening collaboration between Portugal and Brazil in the field of food safety and human health. ICFC2023 featured four sessions that included topics such as the occurrence of contaminants, assessment of human exposure and health impact, sustainability of food systems and collaborative networks and their impact on society. These sessions included a plenary lecture by EFSA on food sustainability, food safety and human health, nine presentations by guest speakers from Europe and Brazil, 17 oral communications by participants and two round tables, with three brief communications each. Around a hundred participants from 12 countries in Europe, Latin America and Africa were present and 57 posters were presented, with a selection for the best poster award.FAPESP, SBCTA, CESAM-UV, INSA, Romer, Waters, R-Biopharm, analitica, SolCampoinfo:eu-repo/semantics/publishedVersio
SRC/RAC1 Pathway and other NIS Plasma Membrane Interactors in NIS Regulation
No full textThe Sodium/Iodide Symporter (NIS) is responsible for the uptake of iodide into thyroid follicular cells, which is required for thyroid hormone production. NIS is present in most differentiated thyroid carcinoma (DTC) cells, allowing radioactive iodine (RAI) to be used to eliminate any residual disease after thyroidectomy. However, in advanced DTC, a significant proportion of metastatic lesions stop taking up iodide and become refractory to RAI therapy. This impairment of iodide uptake is mainly caused by defective functional expression of NIS, due to dysregulated transcriptional and posttranscriptional events. In this presentation, part of a Symposium entitled “Thyroid Cancer Basic: New Molecules for Better Treatments”, I will talk about how we discovered that signaling by the small GTPase RAC1 plays a crucial role in regulating NIS expression, both at the transcriptional and posttranscriptional levels, and how this might impact RAI therapy in advanced DTC.N/
Safety and efficacy of a feed additive consisting of zeolites (≥ 50%) obtained from Neapolitan Yellow Tufa for all animal species (Italiana Zeoliti s.r.l.)
Get PDFFree PMC article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10716728/Following a request from the European Commission, EFSA was asked to deliver a scientific opinion on the safety and efficacy of zeolites (≥ 50%) obtained from Neapolitan Yellow Tufa as a technological additive (functional group: anticaking) for all animal species. The additive is specified to contain not less than 50% of zeolites, namely phillipsite, chabazite and analcime. Neapolitan Yellow Tufa originates from the volcanic activity of Campi Flegrei, Italy. According to the conventional risk assessment, due to a lack of adequate data, the safety of the additive for the target species cannot be established. Based on current knowledge, there is no indication of substantial absorption of the components of the additive and, therefore, of concern for the consumer. The additive poses a risk by inhalation. It is not irritant to the skin. The Panel cannot conclude on the eye irritancy and on the dermal and respiratory sensitisation potential of the additive. As no suitable data in line with the requirements of the Guidance on risk assessment of nanomaterials were provided by the applicant, the potential risks associated with the presence of nanoparticles for the target species, the consumer and the user could not be assessed. The additive is safe for the environment. The additive is considered to be efficacious in feedingstuffs for all animal species at 20,000 mg/kg complete feed.info:eu-repo/semantics/publishedVersio
Childhood Obesity Surveillance Initiative: COSI Portugal 2022
Get PDFAutores: Ana Rito – Centro Colaborativo da Organização Mundial da Saúde para a Nutrição e Obesidade Infantil, Departamento de Alimentação e Nutrição do Instituto Nacional de Saúde Doutor Ricardo Jorge; Sofia Mendes, Inês Figueira – Centro de Estudos e Investigação em Dinâmicas Sociais e Saúde; Maria do Carmo Faria – Direção Regional de Saúde da Madeira; Rita Carvalho, Teresa Santos – Direção Regional de Saúde dos Açores; Susana Cardoso – Administração Regional de Saúde do Norte; Elsa Feliciano – Administração Regional de Saúde do Centro; Rosa Silvério – Administração Regional de Saúde do Alentejo; Teresa Sofia Sancho – Administração Regional de Saúde do Algarve; Ana Dinis, Carla Lacerda Rascôa – Administração Regional de Saúde de Lisboa e Vale do Tejo.
Outros Contributos: Catarina Batista, Rachel Cruz – Centro de Estudos e Investigação em Dinâmicas Sociais e Saúde; Carla Marques – Administração Regional de Saúde de Lisboa e Vale do Tejo.Infográfico - Obesidade Infantil 2022: http://repositorio.insa.pt/handle/10400.18/8631O Childhood Obesity Surveillance Initiative (COSI)/Organização Mundial da Saúde (OMS) é o sistema europeu de vigilância nutricional infantil coordenado pelo Gabinete Regional Europeu da OMS. Tem como principal objetivo criar uma rede sistemática de recolha, análise, interpretação e divulgação de informação descritiva sobre as caraterísticas do estado nutricional infantil de crianças dos 6 aos 8 anos, que se traduz num sistema de vigilância que produz dados comparáveis entre países da Europa e que permite a monitorização da obesidade infantil a cada 2-3 anos. O presente relatório divulga e analisa os dados de prevalência de excesso e obesidade infantil da 6.ª ronda do COSI Portugal, realizada no ano letivo 2021/2022 numa amostra representativa nacional de escolas públicas do 1.º ciclo do Ensino Básico (EB) português.info:eu-repo/semantics/publishedVersio
Trends in antibiotic resistance in Portugal from 2015 to 2022
Get PDFLaboratórios participantes na EARS-Net (ordem alfabética): Laboratório de Microbiologia/Patologia Clínica do: Centro
Hospitalar Barreiro-Montijo, E.P.E.; Centro Hospitalar de Entre Douro e Vouga, E.P.E.; Centro Hospitalar de Leiria, E.P.E.;
Centro Hospitalar de Lisboa Central, E.P.E.; Centro Hospitalar de Lisboa Ocidental, E.P.E.; Centro Hospitalar de Póvoa
de Varzim-Vila do Conde, E.P.E.; Centro Hospitalar de Setúbal, E.P.E.; Centro Hospitalar de Vila Nova de Gaia/Espinho,
E.P.E.; Centro Hospitalar do Alto Ave, E.P.E.; Centro Hospitalar do Baixo Vouga, E.P.E.; Centro Hospitalar do Médio
Ave, E.P.E.; Centro Hospitalar do Médio Tejo, E.P.E.; Centro Hospitalar do Oeste, E.P.E.; Centro Hospitalar do Tâmega
e Sousa, E.P.E.; Centro Hospitalar e Universitário de Coimbra, E.P.E.; Centro Hospitalar Tondela Viseu, E.P.E.; Centro
Hospitalar Universitário Cova da Beira, EPE; Centro Hospitalar Universitário de Santo António, E. P. E.; Centro Hospitalar
Universitário de São João, EPE; Centro Hospitalar Universitário do Algarve, E.P.E.; Clínica Laboratorial Arcos de Valdevez,
Lda.; Centro de Medicina Laboratorial Germano de Sousa (Lisboa); Centro de Medicina Laboratorial Germano de Sousa
(Porto); Hormofuncional - Centro de Hormonologia Funcional, Lda.; Hospital Agostinho Ribeiro - Felgueiras; Hospital
Beatriz Ângelo; Hospital da Cruz Vermelha Portuguesa; Hospital da Horta, E.P.E.; Hospital da Luz Lisboa; Hospital da
Luz Póvoa do Varzim; Hospital da Luz Setúbal; Hospital das Forças Armadas (Pólo Lumiar); Hospital das Forças Armadas
(Pólo Porto); Hospital de Braga, E.P.E.; Hospital de Cascais Dr. José de Almeida, P.P.P.; Hospital de Santo Espírito da Ilha
Terceira, E.P.E.R.; Hospital de Vila Franca de Xira, E.P.E.; Hospital Distrital da Figueira da Foz, E.P.E.; Hospital Distrital
de Santarém, E.P.E.; Hospital do Divino Espírito Santo de Ponta Delgada, E.P.E.; Hospital do Espírito Santo de Évora,
E.P.E.; Hospital Dr. Francisco Zagalo – Ovar; Hospital Dr. Nélio Mendonça (SESARAM); Hospital Garcia de Orta, E.P.E.;
Hospital Lusíadas Lisboa; Hospital Lusíadas Porto; Hospital Professor Doutor Fernando Fonseca, E.P.E.; Hospital SAMS;
Hospital Santa Maria Maior, E.P.E.; Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E. (IPO Coimbra);
Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E. (IPO Lisboa); Instituto Português de Oncologia do Porto
Francisco Gentil, E.P.E. (IPO Porto); Labeto, Centro de Análises Bioquímicas S.A.; Laboratório Aeminium, Lda; Laboratório
de Análises Clínicas Dr. Joaquim Chaves; Laboratório de Análises Clínicas Dra. Albina Filomena Marques; Laboratório de
Análises Clínicas Fernão Magalhães Lda; Laboratório de Análises Clínicas Flaviano Gusmão, Lda; Laboratório de Análises
Clínicas João Lamartine Dias, Lda; Laboratório de Análises Clínicas Soares & Figueiredo; Medicina Laboratorial Dr. Carlos
Torres SA (Unilabs); Santa Casa da Misericórdia de Vila do Conde; SYNLAB Faro; SYNLAB Pr. Espanha. SYNLABHEALTH
II, S.A.; SYNLAB Torres Novas; Synlabhealth Centro, Unipessoal Lda; Unidade Local de Saúde da Guarda, E.P.E.; Unidade
Local de Saúde de Castelo Branco, E.P.E.; Unidade Local de Saúde de Matosinhos, E.P.E.; Unidade Local de Saúde do
Alto Minho, E.P.E.; Unidade Local de Saúde do Baixo Alentejo, E.P.E.; Unidade Local de Saúde do Litoral Alentejano, E.P.E.;
Unidade Local de Saúde do Nordeste, E.P.E.; Unidade Local de Saúde do Norte Alentejano, E.P.E.info:eu-repo/semantics/publishedVersio
Consumers’ perception and consumption behaviour concerning red fruits and green leafy vegetables in Portugal, 2023
Get PDFinfo:eu-repo/semantics/publishedVersio